BSECompany UpdateAuditor Change11 Aug 2026
Sandu Pharmaceuticals Ltd
Appointment of M/s Dave & Dave Chartered Accountant as statutory auditor subject to approval of the shareholder
Sandu Pharmaceuticals Ltd has announced the appointment of M/s Dave & Dave Chartered Accountants as statutory auditors for a first term of five consecutive years, subject to approval of the shareholders.
BSECompany UpdateResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Intimation about the date of the annual General Meeting
Sandu Pharmaceuticals Ltd has announced the date of its annual General Meeting to be held on September 11, 2026. The meeting will be conducted through Video Conferencing (VC)/Other Audio-Visual Means (OAVM). The company has also recommended the proposal for obtaining approval of the Members at the ensuing Annual General Meeting for the continuation of Material Related Party Transactions with M/s. Sandu Brothers Private Limited.
BSECorp. ActionResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Intimation about the Record date
Sandu Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 11, 2026, where it approved the unaudited standalone financial results for the quarter ended June 30, 2026, and other business matters, including the record date for determining the eligibility of members entitled to receive the proposed dividend for the financial year ended March 31, 2026.
BSECorp. ActionResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Intimation about Book closure for AGM
Sandu Pharmaceuticals Ltd has announced the outcome of its Board Meeting held on August 11, 2026, where it approved the unaudited standalone financial results for the quarter ended June 30, 2026, and other business matters. The company has also announced the book closure for its AGM on September 4-11, 2026, and recommended the approval of material related party transactions with Sandu Brothers Private Limited.
BSECompany UpdateResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Outcome and results of the Board Meeting dated 11.08.2026
Sandu Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The company also approved the convening of its 41st Annual General Meeting to be held on September 11, 2026, through video conferencing. Additionally, the Board recommended the proposal for obtaining approval for material related party transactions with Sandu Brothers Private Limited and approved the appointment of Dave & Dave, Chartered Accountants as Statutory Auditors for a first term of five consecutive years.
BSEResultResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Unaudited Financials For ended 30.06.2026
Sandu Pharmaceuticals Ltd has announced unaudited financial results for the quarter ended June 30, 2026, with the board approving the results and recommending the appointment of new statutory auditors. The company also announced the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the continuation of material related party transactions with Sandu Brothers Private Limited.
BSECompany UpdateResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Outcome of the Board Meeting 11.08.2026
Sandu Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The company also approved the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the continuation of material related party transactions with Sandu Brothers Private Limited. Additionally, the Board approved the appointment of M/s. Dave & Dave, Chartered Accountants, as the Statutory Auditors of the Company for a first term of five consecutive years.
BSEBoard MeetingResults11 Aug 2026
Sandu Pharmaceuticals Ltd
Outcome of the Board Meeting
Sandu Pharmaceuticals Ltd approved its unaudited standalone financial results for Q1 FY2026-27, with the board of directors taking note of the statement of utilisation and statement of deviation(s) in utilisation of funds for the quarter ended June 30, 2026. The company also approved the convening of its 41st Annual General Meeting on September 11, 2026, and recommended the proposal for obtaining approval of the members at the ensuing Annual General Meeting for the continuation of material related party transactions with M/s. Sandu Brothers Private Limited. Additionally, the board approved the appointment of M/s. Dave & Dave, Chartered Accountants, as statutory auditors of the company for a first term of five consecutive years.
BSEBoard MeetingResults3 Aug 2026
Sandu Pharmaceuticals Ltd
Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve 1.To consider and approve ....
Sandu Pharmaceuticals Ltd has scheduled a board meeting on 11th August 2026 to consider and approve the standalone unaudited financial results for the quarter ended 30th June 2026.